Clinical Trial Listing

Below are the clinical trials we are currently offering at Banner MD Anderson Cancer Center. Please continue to check back as we will continue to add additional trials to this list.

If you are interested in participating in any of these trials, please call (480) 256-6444.

For more information about these trials please visit ClinicalTrials.gov.

Brain Cancer

Breast Cancer

A Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, hormone Receptor-Positive and HER2/neu Negative Breast Cancer (NCT 01674140)
Principal Investigator: Dr. Mary Cianfrocca

A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer (NCT03155997)
Principal Investigator: Dr. Lida Mina

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment (NCT 02492711) 
Principal Investigator: Dr. Shakeela Bahadur

A Multicenter, Open-label, Phase 2 Study of Imprime PGG and Pembrolizumab in Subjects With Advanced Melanoma Failing Front-line Treatment With Checkpoint Inhibitors (CPI) or Triple Negative Breast Cancer (TNBC) Failing Front-line Chemotherapy for Metastatic Disease (NCT02981303)
Principal Investigator: Dr. Lida Mina

A Phase II, Open Label, Randomised, Multi-centre Study to Assess the Safety and Efficacy of Agents Targeting DNA Damage Repair in Combination With Olaparib Versus Olaparib Monotherapy in the Treatment of Metastatic Triple Negative Breast Cancer Patients Stratified by Alterations in Homologous Recombinant Repair (HRR)-Related Genes (Including BRCA1/2) (VIOLETTE) (NCT03330847)
Principal Investigator: Dr. Shakeela Bahadur

Effect of Preoperative Breast MRI on Surgical Outcomes, Cost and Quality of Life of Women with Breast Cancer (NCT01805076) 
Principal Investigator: Dr. Julie Billar

A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients With Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy (NCT01872975)
Principal Investigator: Dr. Emily Grade

Gastrointestinal Cancer

Biliary Cancer

Phase 1/2 Study of TAS-120 in Patients with Advanced Solid Tumors Harboring FGF/FGFR Aberrations (NCT02052778)
Principal Investigator: Dr. Madappa Kundranda

A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Varlitinib Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Advanced or Metastatic Biliary Tract Cancer as Second Line Systemic Therapy (NCT03093870)
Principal Investigator: Dr. Madappa Kundranda

Colorectal Cancer

A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES) (NCT01349881)
Principal Investigator: Dr. Tomislav Dragovich 

In-Situ Cancer Vaccine: Phase I/IIb, Open-Label Study to Assess the Safety of AlloStim® Immunotherapy in Combination With Cryoablation as Third Line Therapy for Metastatic Colorectal Cancer (NCT02380443) 
Principal Investigator: Dr. Madappa Kundranda

Gastric Cancer

Modular Phase 2 Study to Link Combination Immune-therapy to Patients With Advanced Solid and Hematologic Malignancies. Module 9: PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies (NCT03365791)
Principal Investigator: Dr. Boris Naraev

Liver Cancer

A Phase Ib/II Clinical Study of BBI608 in Combination with Sorafenib or BBI503 in Combination with Sorfenib in Adult Patients with Hepatocellular Carcinoma (NCT02279719)
Principal Investigator: Dr. Madappa Kundranda

A Phase III, Open-label, randomized study of atezolizumab in combination with bevacizumab compared with sorafenib in patients with untreated locally advanced or metastatic hepatocellular carcinoma (NCT03434379)
Principal Investigator: Dr. Madappa Kundranda

Neuroendocrine Tumors

An Open-Label Study of Rovalpituzumab Tesirine in Subjects With Delta-Like Protein 3-Expressing Advanced Solid Tumors (NCT02709889)
Principal Investigator: Dr. Jiaxan Niu

Modular Phase 2 Study to Link Combination Immune-therapy to Patients With Advanced Solid and Hematologic Malignancies. Module 9: PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies (NCT03365791)
Principal Investigator: Dr. Boris Naraev

Pancreatic Cancer

"A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination with nab-Paclitaxel Plus Gemcitabine Compared with Placebo Plus nab-Paclitaxel and Gemcitabine in Subjects with Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma" (NCT02715804)
Principal Investigator: Dr. Tomislav Dragovich

A Phase III Study of BBI-608 plus nab-Paclitaxel with Gemcitabine in Adult Patients with Metastatic Pancreatic Adenocarcinoma (NCT0299373)
Principal Investigator: Dr. Madappa Kundranda

A Randomized Phase 3 Study of AM0010 in Combination with FOLFOX Compared with FOLFOX Alone as Second-line Therapy in Patients with Metastatic Pancreatic Cancer that has Progressed During or Following a First-Line Gemcitabine Containing Regimen (NCT02923921)
Principal Investigator: Dr. Tomislav Dragovich

A Phase 2 Study of BPM31510 (Ubidecarenone, USP) Nanosuspension Injection Administered Intravenously with or without Gemcitabine as 2nd/3rd line therapy in Advanced Pancreatic Cancer Patients (NCT02650804)
Principal Investigator: Dr. Madappa Kundranda

A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Maintenance Olaparib Monotherapy in Patients With gBRCA Mutated Metastatic Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum Based Chemotherapy (NCT02184195)
Principal Investigator: Dr. Tomislav Dragovich

Genitourinary Cancer

Gynecologic Cancer

Leukemia

Lung Cancer

Lymphoma

Phase II Trial of Intravenous Fenretinide (N-(4-hydroxyphenyl) retinamide, 4-HPR) Emulsion for Patients with Relapsed/Refractory Peripheral T-cell Lymphomas (PTCL) (NCT02495415) 
Principal Investigator: Dr. Javier Munoz

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B Cell or T Cell Non-Hodgkin Lymphoma (NHL) (NCT01994382)
Principal Investigator: Dr. Javier Munoz

A Phase I, Open-Label, Multiple-Dose, Dose Escalation and Expansion Study to Investigate the Safety and Pharmacokinetics of the BTK Inhibitor BGB-3111 in Subjects With B-Cell Lymphoid Malignancies (NCT02343120)
Principal Investigator: Dr. Javier Munoz

A Multicenter Open-Label Phase 1b/2 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (NCT02077166)
Principal Investigator: Dr. Javier Munoz

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102) (NCT03039114)
Principal Investigator: Dr. Javier Munoz

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) (NCT02998476)
Principal Investigator: Dr. Javier Munoz

A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel versus Standard of Care Therapy in Subjects with Relapsed/Refractory Diffuse Large B Cell Lymphoma (ZUMA-7) (NCT03391466) 
Principal Investigator: Dr. Javier Munoz

A Phase 2 Study of Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy in Adult Patients With Aggressive B-cell NHL (017006) (NCT03483103)
Principal Investigator: Dr. Javier Munoz

Phase 1 Study of ACTR087, Autologous T Lymphocytes Expressing Antibody Coupled T Cell Receptors (CD16V-41BB-CD3ζ), in Combination with Rituximab, in Subjects with Relapsed or Refractory CD20-Positive B-Cell Lymphoma (NCT02776813)
Principal Investigator: Dr. Javier Munoz

A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL) (ZUMA-2) (NCT02601313)
Principal Investigator: Dr. Javier Munoz

A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (iNHL) (NCT03105336)
Principal Investigator: Dr. Javier Munoz

Melanoma

Myelodysplastic Syndrome (MDS)

Renal Cancer

Solid Tumor